Zimmer Biomet enters $1.5 billion five-year and $1.0 billion 364-day credit facilities
On June 27, 2025, Zimmer Biomet entered a new five-year, $1.5 billion unsecured revolving credit facility and a new 364-day, $1.0 billion revolving credit facility, both with JPMorgan Chase Bank as administrative agent. The new agreements replaced the company's 2024 five-year and 364-day credit agreements, which were terminated, and the filing says the funds will be used for general corporate purposes.
Key points
- Five-year $1.5 billion facility matures June 27, 2030, with two one-year extensions subject to lender consent; an uncommitted feature allows a request to increase it by up to $500.0 million.
- 364-day $1.0 billion facility matures June 26, 2026.
- On June 27, 2025, the company borrowed $50.0 million under the five-year facility to repay part of the terminated 2024 five-year agreement; about $0.7 million was repaid with cash on hand.
- Both agreements require a consolidated indebtedness to consolidated EBITDA ratio of no greater than 4.5 to 1.0, with a possible increase to 5.0 to 1.0 in connection with a qualified material acquisition.
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 30, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.